ICU Medical, Inc. — Q3 2011 Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2011. The company develops, manufactures and sells medical technologies for I.V. therapy, oncology and critical care. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions.
Financial performance and liquidity
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Total revenue | $76.5 million | $75.7 million | $225.7 million | $209.0 million |
| Gross profit / margin | $35.6 million / 46.5% | $34.0 million / 44.9% | $106.4 million / 47.1% | $93.1 million / 44.5% |
| Operating income | $13.3 million | $14.6 million | $39.5 million | $32.8 million |
| Net income | $9.3 million | $9.0 million | $26.8 million | $20.9 million |
| Diluted EPS | $0.65 | $0.65 | $1.89 | $1.51 |
| Operating cash flow | — | — | $36.1 million | $18.8 million |
- Quarterly revenue rose about 1% year over year; net income increased about 3%, while operating income declined about 9%. Nine-month revenue grew about 8%, operating income about 20%, and net income about 28%.
- At September 30, cash and cash equivalents were $66.9 million and investment securities were $52.2 million, totaling $119.1 million, up from $93.4 million at year-end 2010. Cash alone declined $11.9 million during the nine months, chiefly as funds shifted into investments and supported investing activity.
- Current assets were $237.3 million and current liabilities $24.1 million. The balance sheet reports no debt. Stockholders’ equity was $306.9 million.
- Nine-month investing cash outflow was $50.4 million, including $13.8 million in property and equipment purchases and net investment-security purchases of $39.4 million. Financing cash inflow was $1.6 million, including $10.0 million of treasury-stock purchases.
Material changes and operating drivers
- CLAVE sales increased 12% in Q3 and 10% for the nine months. Standard oncology sales increased 222% in Q3 and 160% year to date; TEGO sales grew 80% and 101%, respectively.
- Custom product sales declined 19% in Q3, primarily because Q3 2010 included $4.5 million of non-recurring Hospira orders related to a change in I.V. tubing materials. Nine-month custom sales declined 2%. Standard critical care sales were down 5% in Q3 and 3% year to date, with management citing stronger price competition.
- Hospira accounted for 44% of Q3 revenue and 42% of nine-month revenue. Hospira represented 34% of accounts receivable at September 30. Domestic distributor/direct sales and international sales grew year to date, by 7% and 19%, respectively.
- Higher product mix and lower freight costs supported gross margin, partly offset by Slovakia plant start-up costs and higher raw-material costs. Q3 SG&A increased to $20.4 million from $18.3 million; nine-month R&D increased to $6.4 million from $2.9 million, primarily reflecting project spending and workforce expansion.
Outlook, risks and unusual items
- Management estimated 2011 gross margin of 47%–47.5%, SG&A of approximately 28% of revenue, R&D of approximately 3%, and an effective tax rate of approximately 34%. Estimated 2011 capital expenditures were $17–$19 million. These are estimates, not guarantees.
- Management said existing cash, cash equivalents, investments and expected operating cash generation should fund operations for the next 12 months. It also described expected 2011 growth in CLAVE, oncology, TEGO and certain distribution channels, while anticipating softer critical-care sales and only modest custom-product growth.
- A $2.5 million legal settlement with a former law firm was recorded as a credit to operating expenses in the first nine months. The company also recorded $2.3 million of non-recurring Long Term Retention Plan expense across SG&A and R&D, and $0.8 million of facility-transition termination costs.
- In September, management and the board decided to sell a small product line and focus on core products. Approximately $1.7 million of intangible assets and less than $0.1 million of fixed assets were classified as held for sale; completion was expected in Q4 2011.
- In the ICU Medical v. RyMed patent case, the jury had found infringement and patent validity in 2010. The court granted ICU’s motion for a new trial on one infringement question and denied RyMed’s motions; that retrial was scheduled for May 7, 2012. Management stated routine litigation was not expected to materially affect financial condition or results.
- Key risks include reliance on Hospira and a limited number of customers, increased competition and pricing pressure in critical care, product-development and market-entry uncertainty, raw-material and manufacturing costs, international and foreign-exchange exposure, and possible liquidity or business downturns. The company said it did not hedge foreign-currency exposures.
Important facts for investors to verify
- Whether Hospira sales and receivables concentration changes, and whether the customer relationship or Hospira’s market position weakens.
- Whether growth in CLAVE, oncology and TEGO continues to offset custom-product and critical-care weakness, including competitive pricing effects.
- Whether management’s margin, expense, tax and capital-spending estimates are achieved, and how much of reported earnings reflects one-time settlement and retention-plan items.
- Whether the small product-line sale closes as expected and whether the RyMed retrial or other legal matters produce material outcomes.
- Whether investment liquidity, foreign-exchange exposure and manufacturing-transition costs affect cash generation; the filing reports no debt and states liquidity is expected to cover the next 12 months.